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BACKGROUND: Release of the neuronal protein S-100B into the circulation has been suggested as a specific indication of
neuronal damage. The hypothesis that S-100B is a useful and cost-effective screening tool for the management of minor head
injuries was tested.
METHODS: Fifty consecutive patients sustaining isolated minor head injury were prospectively evaluated in the emergency
room of a Brazilian hospital by routine cranial computed tomography scan. Venous blood samples (processed to serum) were
assssayed for S-100B using a newly developed immunoassay test kit. Twenty-one normal healthy individuals served as negative
controls. Data are presented as median and 25 to 75 percentiles.
RESULTS: Patients reached the emergency room an average of 45 minutes (range: 30–62 minutes) after minor head injury. Six of
50 patients (12%) showed relevant posttraumatic lesions in the initial cranial computed tomography scan and were counted as
positive. The median systemic concentration of S-100B in those patients was 0.75 µg/L (range: 0.66–6.5 µg/L), which was
significantly different (U-test, P < .05) from the median concentration of 0.26 µg/L (range: 0.12–0.65 µg/L), of patients without
posttraumatic lesions as counted by the cranial computed tomography. A sensitivity of 100%, a specificity of 20%, a positive
predictive value of 15%, and a negative predictive value of 100% was calculated for the detection of patients suffering from
intracranial lesions.
CONCLUSIONS: Protein S-100B had a very high sensitivity and negative predictive value and could have an important role in
ruling out the need for cranial computed tomography scan after minor head injury. This appears to be of substantial clinical
relevance, particularly in countries where trauma incidence is high and medical resources are limited, such as in Brazil.
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INTRODUCTION
Risk estimation for clinically relevant intracranial lesions
after minor head injury (MHI) (Glasgow Coma Scale Score
of 13–15 points) remains a major diagnostic challenge. The
gold standard diagnostic tool to rule out posttraumatic lesions
is cranial computed tomography (CCT). The need for an im-
mediate CCT scan after moderate or severe head injury is un-
disputed.1 However, substantial controversy exists regarding
the cost effectiveness of routine CCT scan after a minor head
injury.2,3 Although the reported frequency of intracranial in-
juries, varying from 5.9% to 21.6%,4,5 is much lower than af-
ter moderate or severe head injury, this proportion represents
a high risk group, since prognosis is also dependent on rapid
detection of potentially life-threatening complications, eg,
skull fracture, hemorrhage, or brain edema. Some reports re-
commend routine CCT, because clinical evaluation may not
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always provide sufficient information regarding the decision
for further diagnosis and special treatment, preferably in pa-
tients in whom the level of consciousness and the quality of
neurological examination may have been altered by alcohol,
drugs, or other associated injuries.6,7
Patients at risk are characterized by relevant pathologi-
cal findings in the CCT scan. As shown in a study of 2,766
patients, none required further treatment in the absence of
pathological findings in the initial CCT scan.7,8 However,
due to the large number of patients sustaining minor head
injury, routine CCT scanning and the need for repetitive
neurological supervision, requiring admittance to a ward,
may generate serious financial and logistic burdens, espe-
cially in areas where trauma incidence is high and medi-
cal resources are limited, such as in many parts of Brazil.
If the victim suffers from a posttraumatic intracranial le-
sion, additional neurological symptoms are likely to occur,
ie, focal neurological symptoms, increasing dizziness, or
disturbances of the pupils. Although a CCT scan is usu-
ally performed in this situation, the development of symp-
tomatic intracerebral lesions, such as epidural or subdural
hemorrhages, may have just started and thus might be over-
looked at this point. This delay may cause further damage
or worsen the initial prognosis. Therefore, a rapid and sen-
sitive screening test for the presence of intracranial lesions
in patients suffering from minor MHI is very much needed.
In recent years, measurement of a specific neuronal pro-
tein S-100B released into the circulation has been evaluated
for identification of risk groups among victims sustaining
head trauma.9-12 Protein S-100B is predominantly found in
glial and Schwann cells as well as in neurons; it is normally
released in small amounts due to metabolic cell processes,
but in larger quantities as a consequence of cell damage. It
is known to modulate glial fibrillary acidic protein (GFAP)
and intermediate filament assembly in neuronal and glial
cells as well as proliferation of neuronal cells.13 In physiologi-
cal conditions, it has been detected in serum only in very
low amounts, requiring a highly sensitive immunoassay.14
The half-life is about 80-120 minutes. Therefore, measure-
ment is valid only if the blood sample is obtained within 2
hours from trauma. However, an early peak of S-100B se-
rum levels after severe head injury or ischemic brain condi-
tions reflects cellular damage and elevated permeability of
the blood brain barrier.14,15 Additional studies also indicate
S-100B as a promising quantitative, objective tool for iden-
tifying high-risk patients with MHI, including those under
the influence of alcohol.9,10,12,16,17 There is no influence of gen-
der on S-100B measurement. In infants, the normal concen-
tration is higher, and there is a current study addressing year-
adjusted concentration ranges. The majority of studies have
included only patients 18 years old or older.
The aim of this pilot study was to further investigate the
diagnostic value of S-100B serum measurements in patients
suffering from MHI. Therefore the hypothesis that S-100B
may be a rapid and useful screening tool for the manage-
ment MHI in Brazilian patients, enabling the reduction of
often unnecessary and costly CCT scans was tested.
PATIENTS AND METHODS
This study was approved by the Ethics Committee of
João XXIII Hospital. João XXIII Hospital is a large emer-
gency center located in downtown Belo Horizonte (2.5 mil-
lion inhabitants), in central Brazil. In 2003 during Septem-
ber and October, we prospectively studied 50 consecutive
patients sustaining isolated MHI, defined by a Glasgow
Coma Scale Score (GCS) of 13 to 15 and presenting at least
one of the following symptoms: amnesia, loss of conscious-
ness, nausea, vomiting, vertigo, or severe headache on ad-
mission. Patients with focal neurological deficits were ex-
cluded. In addition, a negative control group of healthy vol-
unteers (n = 21) was studied. Informed consent was given
by volunteers, patients or relatives. Venous blood samples
were drawn on admission and processed to serum. The
deep-frozen serum samples were transported to the Ludwig-
Maximilians-University Hospital in Munich, Germany, and
levels of S-100B were measured using a newly developed
heterogeneous immunoassay (Elecsys 2010®) according to
the manufacturer’s instructions. In our earlier studies,12,17
we established a cut-off point at a concentration of 0.1 µg/
L of S-100B, which was the highest level measured in
healthy volunteers without any sign of intracranial injury.
Thus, patients presenting a S-100B level below 0.1 µg/L
were defined as “negative,” while those with concentration
above 0.1 µg/L were defined as “positive.”
Cranial computed tomography (CCT) was performed
within 6 hours of emergency room admission, and radio-
logical findings were defined as pathological (CCT+) if in-
tracranial hemorrhage, skull fracture, and/or diffuse brain
swelling (edema) were detected. Sensitivity, specificity,
positive, and negative predictive values of S-100B serum
levels were calculated for signs of intracranial injury at the
initial CCT scan.
Statistical analysis was performed using the Mann-
Whitney rank sum test and Dunn´s method (SigmaStat 2.0,
Jandel Corporation); significance was accepted at P < .05.
Data are shown as median and 25%–75% quartile.
RESULTS
Fifty consecutive patients (28 males, 22 females) sus-
taining isolated minor head injury (MHI) were included.
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There were 37 patients with a GCS of 15, 11 with a GCS
of 14, and 2 with a GCS of 13. Out of these, 6 patients
had trauma-relevant intracranial lesions according to the
radiological criteria given in the Patients and Methods sec-
tion and were thereby counted as CCT+. In contrast, 44
patients had none of these lesions and were counted as
CCT–.
The median time interval from trauma to blood sam-
pling for the S-100B assay was 82 minutes (25%-75% quar-
tiles: 60-110 min). The median serum concentration of S-
100B was 0.29 µg/L (25%-75% quartiles: 0.14–0.76 µg/L)
for the entire MHI group, which was significantly elevated
(P < .001) compared to that of the negative control group
of 21 healthy volunteers (median, 0.04 µg/L; 25%-75%
quartiles: 0.03–0.05 µg/L). As shown in Figure 1, MHI pa-
tients (n = 44) without radiological findings exhibited a
median S-100B serum value of 0.26 µg/L (25%-75% quar-
tiles: 0.12–0.65 µg/L), which was significantly lower (P <
.05) than the levels of CCT+ patients (n = 6); median: 0.75
µg/L; 25%-75% quartiles: 0.62–6.5 µg/L).
The contingency table (Table 1) based on the cut-off at
0.1 µg/L demonstrates that all 6 individuals presenting
trauma-relevant intracranial lesions in the initial CCT scan
exhibited a serum concentration above the cut-off level and
were thereby detected correctly as CCT+/S-100B+. Nine
individuals were classified as S-100B negative and had no
lesions in CCT scan. From those 9 patients, 8 presented a
GCS of 15 and only one presented GCS of 14.
In 35 patients, the S-100B serum concentrations were
above the cut-off at 0.1 µg/L and were counted as S-100B+
but as negative for intracranial lesions from the CCT scan
(CCT-). From these data, for the ruling-out test of S-100B
measurement, a sensitivity of 100%, a negative predictive
value of 100%, a specificity of 20%, and a positive pre-
dictive value of 15% were calculated.
The receiver operating curve (ROC) analysis (Figure 2)
revealed an area under the curve (AUC) of 0.82 (95% CI
0.69–0.96) for discrimination of patients according to their
S-100B levels into the groups CCT+ or CCT-, which was
highly significant (P < .0001).
DISCUSSION
Although the studied patient population was limited, our
results demonstrate that measurement of serum S-100B lev-
els in victims sustaining isolated minor head injury (MHI)
is a highly sensitive procedure for the detection of intrac-
ranial injury. Due to its excellent negative predictive value,
a normal level of protein S-100B may rule out the need
Table 1 - Contingency table of S-100B measurements and
cranial computed tomography (CCT)-findings
CCT+ CCT-
S-100B > 0.1 µg/L 6 35 positive predictive
value 15%




Sensitivity, specificity, positive, and negative predictive value for the
distribution of pathological S-100B values and cranial computed tomography
(CCT) scan findings. Positive CCT scan (CCT+) represents signs of a relevant
posttraumatic intracerebral pathology, eg, hemorrhage, diffuse brain
swelling, or skull fracture, whereas CCT- stands for the absence of trauma-
related signs.
Figure 1 - S-100B serum concentrations in healthy controls (n=21) and
patients suffering from isolated minor head injury (n = 50). Positive cranial
computed tomography (CCT+, n = 6) means the presence of intracranial
hemorrhage, skull fracture, or diffuse brain swelling, whereas CCT- (n =
44) reflects the absence of those findings. Median serum concentrations of
S-100B were significantly different between CCT- and CCT+ patients ( = P
< .05 in the U-test).
Figure 2 - Receiver operating curve analysis in 50 patients with minor head
trauma
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for a CCT scan. The speed (determination within 17 min-
utes) and lower cost of this diagnostic screening tool (about
10%–20% of a CCT scan), suggest a significant positive
impact for S-100B measurements on the management of
MHI patients in countries such as Brazil. The cost of S100B
would probably vary between 10 and 20 US dollars, and
needle-to-result time would be about 20 minutes. However,
if a patient presents classical neurological symptoms, such
as a wide pupil or loss of conciousness, a CT scan should
be performed even is the S-100B is below the cut-off value.
The benefit of a triage test for this patient population
is obvious. The management of patients suffering from
MHI is associated with related problems concerning diag-
nosis and treatment.18 The incidence of MHI in Brazil is
not known, but we believe it may be as high or even higher
than that observed in the USA, causing 400,000 to 450,000
admissions per year.19 Due to the large number of MHI vic-
tims, routine CCT scanning of these patients would gener-
ate financial and logistical burdens for health systems, es-
pecially in developing countries where medical resources
are limited and CT availability may be limited to some
larger cities. Based on the 100% negative predictive value
of protein S-100B measurement, a much more selective
approach to CCT scanning for those patients can be
achieved. In addition, the lack of an influence of alcohol
use on the S-100B determination is a highly desired char-
acteristic of this test.12,15,17 The first promising results re-
garding this diagnostic test showed a strong correlation be-
tween serum levels of S-100B and the outcomes of severe
head injury victims as well as of patients suffering from a
cerebral hypoxia during circulatory arrest.20,21-23 A study on
the neurobehavioral outcomes revealed that MHI patients
with a serum concentration above 0.14 µg/L have a 6.9 like-
lihood ratio for developing posttraumatic neuropsychologi-
cal deficits.24 Yet, the authors did not mention the frequen-
cies of pathological radiological results in comparison to
the S-100 B data. In an earlier study, Rothoerl et al com-
pared levels of S-100B serum concentrations for 11 patients
with MHI versus 30 patients with severe head injury using
a radioimmunoassay method for S-100B measurement.15
The MHI group revealed a mean serum concentration of
0.35 µg/L versus 2.6 µg/L for the severe head injury group.
From these concentrations, the authors defined a cut-off
level of 0.5 µg/L to indicate relevant brain injury.15 Yet, this
study suffered from the limitation of a great variation of
the interval between trauma and blood sampling, which was
up to 330 minutes, and had no negative control group.
Hence, the diagnostic value of measurement of S-100B in
plasma of MHI patients for identifying high-risk groups still
remained unclear; importantly, a reliable cut-off level for
a safe differentiation between uncomplicated and problem-
atic MHI had not been determined.
Therefore, Biberthaler et al conducted 2 studies on MHI
patients establishing a reliable cut-off value of 0.1 µg/L.12,16
The review of Klauber et al analyzing data of the USA Na-
tional Traumatic Coma Data Bank clearly showed that mor-
tality of patients suffering from MHI and an initial GCS of
13-15 points with an occult intracerebral lesion is conside-
rably higher than that estimated for the risk of death.25 These
lesions, eg intracranial hematomas or diffuse brain swelling,
express themselves clinically within a time frame of hours
to days after first neurological examination.26 Although not
all of these symptoms have to be treated by immediate sur-
gery, close clinical observation is essential, because any rel-
evant posttraumatic intracerebral lesion may result in severe
disability or even early death.8 It is well known that screen-
ing methods that are intended to identify high-risk groups
have to be very sensitive. In this respect, routine testing of
newborn infants for phenylketonuria or neonatal hypothy-
roidism, which are 2 exemplary diseases of similar deleteri-
ous consequences for the affected patient if they are missed
within the first weeks of life,27 presents a comparable prob-
lem. Because measurement of serum S-100B is proposed as
a screening method of a similar potentially life-threatening
complication in patients suffering from MHI, a low cut-off
point has to be established providing high sensitivity for the
test. Therefore, the aim of our present study was to analyze
the diagnostic value of measurements of S-100B levels in
serum of patients with MHI and to re-evaluate the cut-off
level for practical use. With a cut-off point of 0.1 µg/L, sen-
sitivity and negative predictive value were 100%, but
specificity and positive predictive value were only 20% and
15% at an overall prevalence of 12% of intracerebral injury
signs on our present study.
In our study, 60% of the patients defined as “positive”
by the S-100B assay did not show relevant intracranial le-
sions in the CCT scan. Nevertheless, our data indicated that
a reduction of 40% of routine CCT scans on MHI patients
might be possible by using this simple and practical test.
Last but not least, this is a first report on serum S-100B
levels in a Brazilian population, either healthy or trauma-
tized. They were shown to be similar to those of European
individuals. This is especially interesting in view of the fact
that in addition to neuronal cells, melanocytes may also
be able to release S-100B into the circulation. Thus, the
origin of elevated levels of S-100B in Brazilian MHI pa-
tients appears to be due to release from neuronal cells rather
than from melanocytes.
In conclusion, in spite of the low specificity for the de-
tection of intracranial lesions, using a cut-off value of 0.1
µg/L of serum S-100B as determined by this heterogene-
ous immunoassay system, we find that it has a high sensi-
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tivity and, most importantly, a 100% negative predictive
value, ruling out the need for CCT scan in MHI patients
with a serum S-100B concentration below 0.1µg/L. These
results appear to be of substantial clinical and financial rel-
evance for countries such as Brazil where trauma incidences
are very high and medical resources are limited.
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RESUMO
Poli de Figueiredo LF, Biberthaler P, Simao Filho C, Hauser
C, Mutschler W, Jochum M. Medida da proteína S-100B
sérica para classificação de risco no trauma craniano leve
– estudo piloto no Brasil. Clinics. 2006;61(1):41-6.
INTRODUÇÃO: A liberação da proteína neuronal S-100B
na circulação tem sido sugerida como indicadora de dano
neuronal. Foi testada a hipótese de que a S-100B é um
marcador útil e custo efetivo para a triagem de pacientes
com trauma craniano leve.
MÉTODO: Cinqüenta pacientes consecutivos com trauma
craniano isolado foram prospectivamente avaliados na sala
de emergência de um Centro de Trauma brasileiro pela
tomografia computadorizada de crânio e por amostras de san-
gue venoso, para a medida no soro da proteína S-100B uti-
lizando um teste recentemente desenvolvido; 21 pessoas nor-
mais foram utilizadas como controles negativos. Os resulta-
dos são apresentados como mediana e percentis 25-75.
RESULTADOS: Os pacientes chegaram ao Centro de Trau-
ma em média 45 min (30-62) após o trauma craniano leve.
Seis dos 50 pacientes tiveram lesões pós-traumáticas rele-
vantes segundo a tomografia computadorizada de crânio
inicial (12%) e foram considerados como positivos. A con-
centração mediana de S-100B nestes pacientes foi de
0,75µg/L (0,66-6,5), significativamente maior (U-teste,
p<0,05) do que a concentração mediana de 0,26µg/L (0.12-
0.65) dos pacientes sem lesões pós-traumáticas, segundo a
tomografia computadorizada de crânioCCT-. O cálculo para
a detecção dos pacientes com lesões intra-cranianas reve-
lou sensibilidade de 100%, especificidade de 20%, valor
preditivo positivo de 15% and valor preditivo negativo de
100%.
CONCLUSÃO: A proteína S-100B tem altas taxas de
sensibilidade e valor preditivo negativo, podendo ter um
importante papel para descartar a necessidade de
tomografia de crânio após trauma craniano leve. Acredita-
mos que este achado é de relevância clínica, principalmente
em países onde o trauma é muito frequente e os recursos
médicos limitados.
UNITERMOS: Tomografia de crânio. Trauma de crânio.
Escala de Coma de Glasgow. Proteína S100B.
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